-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $35

Benzinga·07/15/2025 14:46:04
Listen to the news
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $37 to $35.